Recent updates in multimodal treatment are reshaping gastric cancer care, impacting surgical strategies and patient outcomes.

• Laparoscopic and robotic gastrectomy are now standard in Asia, supported by major trials like JCOG0912 and K-LASS02.
• The FLOT chemotherapy regimen is becoming the global standard, while SOX and XELOX gain traction in Asia.

Surgeons should consider integrating immunotherapy based on emerging trial results for select patients.

• Ongoing trials are studying the role of conversion surgery in stage IV cases, highlighting the need for personalized multi-disciplinary approaches.